Related Experiment Videos
Formulation of medicines for children
1Royal Liverpool Children's NHS Trust, Liverpool, UK. tony.nunn@rlc.nhs.uk
British Journal of Clinical Pharmacology
|June 14, 2005
Summary
Developing pediatric formulations presents significant challenges, particularly in taste-masking and age-appropriate dosage forms for children. Addressing these issues is crucial for improving medication compliance and therapeutic outcomes in pediatric populations.
Area of Science:
- Pharmaceutical Sciences
- Pediatric Pharmacology
Background:
- Pediatric drug formulation requires age-adapted dosage forms and effective taste-masking for orally administered medications.
- Childhood maturation impacts both drug dosing (developmental pharmacology) and the ability to manage different dosage forms and devices.
Purpose of the Study:
- To highlight the challenges in developing pediatric formulations, focusing on accurate dosing for varying ages and weights.
- To discuss the suitability of adult dosage forms for pediatric use and the importance of taste-masking in liquid formulations.
- To identify knowledge gaps and industry challenges in creating universally suitable pediatric preparations.
Main Methods:
- Review of current challenges in pediatric drug formulation.
- Discussion of age-specific administration abilities and the role of developmental pharmacology.
- Analysis of various dosage forms (liquids, oro-dispersible tablets, granules) and their limitations in pediatric use.
Main Results:
- Accurate dose administration in pediatric patients requires formulations adaptable to wide age and weight variations.
- Taste-masking is critical for liquid medicines in infants and younger children.
- Sophisticated formulations like oro-dispersible tablets and granules may be necessary, but excipient limitations exist.
Conclusions:
- Significant knowledge gaps and industry challenges persist in developing adequate pediatric formulations.
- Poor formulation acceptability can negatively impact patient compliance, prescribing practices, and commercial viability.
- Further research and clinical feedback are essential, with regulatory guidance forthcoming (CHMP points to consider document).